Clinical implications of the molecular subtypes of diffuse large B-cell lymphoma

References

• Alizadeh AA, Eisen MB, Davis RE, . Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503–511.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Chan WC, . The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937–1947.
   PubMed Web of Science ®Google Scholar
• Lossos IS, Okada CY, Tibshirani R, . Molecular analysis of immunoglobulin genes in diffuse large B-cell lymphomas. Blood 2000;95:1797–1803.
   PubMed Web of Science ®Google Scholar
• Lossos IS, Alizadeh AA, Eisen MB, . Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas. Proc Natl Acad Sci USA 2000;97:10209–10213.
   PubMed Web of Science ®Google Scholar
• Davis RE, Brown KD, Siebenlist U, . Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001;194:1861–1874.
   PubMed Web of Science ®Google Scholar
• Jost PJ, Ruland J. Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood 2007;109:2700–2707.
   PubMed Web of Science ®Google Scholar
• Davis RE, Ngo VN, Lenz G, . Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010;463:88–92.
   PubMed Web of Science ®Google Scholar
• Kato M, Sanada M, Kato I, . Frequent inactivation of A20 in B-cell lymphomas. Nature 2009;459:712–716.
   PubMed Web of Science ®Google Scholar
• Lenz G, Davis RE, Ngo VN, . Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 2008;319:1676–1679.
   PubMed Web of Science ®Google Scholar
• Ngo VN, Young RM, Schmitz R, . Oncogenically active MYD88 mutations in human lymphoma. Nature 2011;470:115–119.
   PubMed Web of Science ®Google Scholar
• Lenz G, Wright G, Dave SS, . Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008;359:2313–2323.
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, . Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275–282.
   PubMed Web of Science ®Google Scholar
• Choi WW, Weisenburger DD, Greiner TC, . A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 2009;15:5494–5502.
   PubMed Web of Science ®Google Scholar
• Meyer PN, Fu K, Greiner TC, . Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol 2011;29:200–207.
   PubMed Web of Science ®Google Scholar
• Muris JJ, Meijer CJ, Vos W, . Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma. J Pathol 2006;208:714–723.
   PubMed Web of Science ®Google Scholar
• Gutierrez-Garcia G, Cardesa-Salzmann T, Climent F, . Gene expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Blood 2011;117:4836–4843.
   PubMed Web of Science ®Google Scholar
• Rayman N, Lam KH, van der Holt B, . Prognostic relevance of immunohistochemical subclassification of diffuse large B-cell lymphoma in two prospective phase III clinical trials. Clin Lymphoma Myeloma Leuk 2011;11:23–32.
   PubMed Web of Science ®Google Scholar
• de Jong D, Rosenwald A, Chhanabhai M, . Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications—a study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol 2007;25:805–812.
   PubMed Web of Science ®Google Scholar
• de Jong D, Xie W, Rosenwald A, . Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium). J Clin Pathol 2009;62:128–138.
   PubMed Web of Science ®Google Scholar
• Rimsza LM, Wright GW, Schwartz M, . Classification of diffuse large B cell lymphoma into germinal center and activated B cell subtypes using a nuclease protection assay on paraffin embedded tissues. Clin Cancer Res 2011;17:3727–3732.
   PubMed Web of Science ®Google Scholar
• Shaknovich R, Geng H, Johnson NA, . DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma. Blood 2010;116:e81–e89.
   PubMed Web of Science ®Google Scholar
• Montes-Moreno S, Martinez N, Sanchez-Espiridion B, . MicroRNA expression in diffuse large B-cell lymphoma treated with chemoimmunotherapy. Blood 2011;118:1034–1040.
   PubMed Web of Science ®Google Scholar
• Jardin F, Jais JP, Molina TJ, . Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study. Blood 2010;116:1092–1104.
   PubMed Web of Science ®Google Scholar
• van Galen JC, Muris JJ, Giroth CP, . Expression of TNF-receptor associated factor 2 correlates with poor progression-free survival time in ABC-like primary nodal diffuse large B-cell lymphomas. Histopathology 2008;52:578–584.
   PubMed Web of Science ®Google Scholar
• van Galen JC, Muris JJ, Oudejans JJ, . Expression of the polycomb-group gene BMI1 is related to an unfavourable prognosis in primary nodal DLBCL. J Clin Pathol 2007;60:167–172.
   PubMed Web of Science ®Google Scholar
• Li D, Xie P, Mi C. Primary testicular diffuse large B-cell lymphoma shows an activated B-cell-like phenotype. Pathol Res Pract 2010;206:611–615.
   PubMed Web of Science ®Google Scholar
• Al-Abbadi MA, Hattab EM, Tarawneh MS, . Primary testicular diffuse large B-cell lymphoma belongs to the nongerminal center B-cell-like subgroup: a study of 18 cases. Mod Pathol 2006;19:1521–1527.
   PubMed Web of Science ®Google Scholar
• Carbone A. Primary diffuse large B-cell lymphoma of the breast: an aggressive subgroup with nongerminal center B-cell-like phenotype. Am J Hematol 2009;84:129–130.
   PubMed Web of Science ®Google Scholar
• Yoshida S, Nakamura N, Sasaki Y, . Primary breast diffuse large B-cell lymphoma shows a non-germinal center B-cell phenotype. Mod Pathol 2005;18:398–405.
   PubMed Web of Science ®Google Scholar
• Braaten KM, Betensky RA, de Leval L, . BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma. Clin Cancer Res 2003;9:1063–1069.
   PubMed Web of Science ®Google Scholar
• Camilleri-Broet S, Criniere E, Broet P, . A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood 2006;107:190–196.
   PubMed Web of Science ®Google Scholar
• Lin CH, Kuo KT, Chuang SS, . Comparison of the expression and prognostic significance of differentiation markers between diffuse large B-cell lymphoma of central nervous system origin and peripheral nodal origin. Clin Cancer Res 2006;12:1152–1156.
   PubMed Web of Science ®Google Scholar
• Hoefnagel JJ, Dijkman R, Basso K, . Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling. Blood 2005;105:3671–3678.
   PubMed Web of Science ®Google Scholar
• Akasaka T, Lossos IS, Levy R. BCL6 gene translocation in follicular lymphoma: a harbinger of eventual transformation to diffuse aggressive lymphoma. Blood 2003;102:1443–1448.
   PubMed Web of Science ®Google Scholar
• Lossos IS, Levy R. Mutation analysis of the 5′ noncoding regulatory region of the BCL-6 gene in non-Hodgkin lymphoma: evidence for recurrent mutations and intraclonal heterogeneity. Blood 2000;95:1400–1405.
   PubMed Web of Science ®Google Scholar
• Davies AJ, Rosenwald A, Wright G, . Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms. Br J Haematol 2007;136:286–293.
   PubMed Web of Science ®Google Scholar
• Kramer MH, Hermans J, Wijburg E, . Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood 1998;92:3152–3162.
   PubMed Web of Science ®Google Scholar
• Ladanyi M, Offit K, Jhanwar SC, . MYC rearrangement and translocations involving band 8q24 in diffuse large cell lymphomas. Blood 1991;77:1057–1063.
   PubMed Web of Science ®Google Scholar
• Klapper W, Stoecklein H, Zeynalova S, . Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Leukemia 2008;22:2226–2229.
   PubMed Web of Science ®Google Scholar
• Niitsu N, Okamoto M, Miura I, . Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations. Leukemia 2009;23:777–783.
   PubMed Web of Science ®Google Scholar
• Savage KJ, Johnson NA, Ben-Neriah S, . MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood 2009;114:3533–3537.
   PubMed Web of Science ®Google Scholar
• Xicoy B, Ribera JM, Mate JL, . Immunohistochemical expression profile and prognosis in patients with diffuse large B-cell lymphoma with or without human immunodeficiency virus infection. Leuk Lymphoma 2010;51:2063–2069.
   PubMed Web of Science ®Google Scholar
• Chadburn A, Chiu A, Lee JY, . Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium clinical trials 010 and 034. J Clin Oncol 2009;27:5039–5048.
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Little RF, Pittaluga S, . The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. Blood 2010;115:3017–3024.
   PubMed Web of Science ®Google Scholar
• Fu K, Weisenburger DD, Choi WW, . Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol 2008;26:4587–4594.
   PubMed Web of Science ®Google Scholar
• van Imhoff GW, Boerma EJ, van der Holt B, . Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. J Clin Oncol 2006;24:4135–4142.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Broccoli A, Stefoni V, . Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients. Cancer 2010;116:5667–5675.
   PubMed Web of Science ®Google Scholar
• Costa LJ, Feldman AL, Micallef IN, . Germinal center B (GCB) and non-GCB cell-like diffuse large B cell lymphomas have similar outcomes following autologous haematopoietic stem cell transplantation. Br J Haematol 2008;142:404–412.
   PubMed Web of Science ®Google Scholar
• Hallack Neto AE, Dulley FL, Coelho Siqueira SA, . Prognostic impact of diffuse large B-cell lymphoma subgroups in patients undergoing autologous SCT. Bone Marrow Transplant 2009;43: 323–325.
   PubMed Web of Science ®Google Scholar
• Nyman H, Jantunen E, Juvonen E, . Impact of germinal center and non-germinal center phenotypes on overall and failure-free survival after high-dose chemotherapy and auto-SCT in primary diffuse large B-cell lymphoma. Bone Marrow Transplant 2008;42:93–98.
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Zelenetz AD, Kewalramani T, . Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL. Blood 2005;106:3383–3385.
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Pittaluga S, Czuczman MS, . Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood 2009;113:6069–6076.
   PubMed Web of Science ®Google Scholar
• Ruan J, Martin P, Furman RR, . Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol 2011;29:690–697.
   PubMed Web of Science ®Google Scholar
• Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL, . Higher response to lenalidomide in relapsed/refractory diffuse large b-cell lymphoma in nongerminal center b-cell-like than in germinal center b-cell-like phenotype. Cancer 2011 Apr 14.
   PubMed Web of Science ®Google Scholar